Potential winners of Germany's upcoming elections are pledging to abolish private medical insurance (PKV). The move could spell disaster for the whole healthcare sector: it accounts for 37% of all expenditure.
The direct-to-consumer or B2C diagnostics sector began well before Covid. Over the past decade, increasing numbers of people have used at-home testing kits to screen for a variety of diseases (cancers, cardiac diseases and STIs), as well as to evaluate genetic susceptibility and find out about their ancestry.
The consolidation of The Netherlands' non-profit outpatient diagnostics sector by for-profit groups is expected to pick up in the coming months after a delay due to Covid, a partner at Deloitte tells HBI.
While sales and profits at Europe's largest traditional players swelled during the pandemic, the sector also saw an influx of non-traditional players. The trend has seen biotech companies start to sell their COVID-19 tests direct to the customer.
Brazilian hospital group Rede D'Or has pulled back on its attempt to takeover imaging group Alliar after it became clear it could not take control. However, large lab group Fleury has now also thrown its hat into the ring for a stake.